Skip to Main Content

A mostly overlooked component of CAR-T cells has a surprisingly strong effect on the cancer-fighting cells’ behavior, scientists reported on Tuesday, including in ways that might affect their safety and efficacy.

The component is called the co-stimulatory domain, and the two CAR-T therapies approved last year to treat forms of leukemia and lymphoma — Yescarta and Kymriah — use different ones.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Comments are closed.